SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 693.35-0.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Felix B who wrote (2649)2/8/2019 12:12:02 AM
From: Miljenko Zuanic   of 3557
 
Most likely bispecific (or costimulatory bispecific) will be ultimately (initially as mono) develop as combo. The most intriguing candidate, that SNY opted out, is anti-CTLA4, where several bios try to challenge BMY. From the SNY repertoire it is anti-TGFrbeta! Did REGN refuse to pay SNY co-development expense on this candidate? Or SNY refuse to share candidate????? I would love to know what is going on?

Of note, from 10K, "As of December 31, 2018, we had approximately 7,400 full-time employees."...where is end? Expense will skyrocket in coming Qs. Do they have income to cover it???? As a patriot, I am all in, as SH....concerned!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News